Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-869/kg · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ABT-869 0.25 mg/kg | EXPERIMENTAL | Approximately half of the subjects were randomized to receive the high dose |
| ABT-869 0.10 mg/kg | EXPERIMENTAL | Approximately half of the subjects were randomized to receive the Low Dose |
| Name | Type | Description |
|---|---|---|
| ABT-869 .25 mg/kg | DRUG | Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight. |
| ABT-869 0.10 mg/kg | DRUG | Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight. |
Inclusion Criteria: * Subject must be histologically or cytologically diagnosed with advanced or metastatic NSCLC * Subjects must have at least one lesion measurable by CT scan as defined by RECIST * The measurable lesion may have not received radiation therapy * Subject has an Eastern Cooperative ...
ABT-869 is an investigational small molecule being studied in oncology. It has been evaluated in clinical trials for advanced renal cell carcinoma, advanced non-small cell lung cancer (NSCLC), advanced or metastatic NSCLC, advanced solid tumors, advanced colorectal cancer, and metastatic breast cancer. It is not approved and remains in clinical development.
ABT-869 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The drug has completed Phase 2 trials in oncology indications.
ABT-869 has completed Phase 2 clinical trials. It is an investigational drug and has not been approved by regulatory authorities. Its development status is based on completed trials in advanced renal cell carcinoma and non-small cell lung cancer.
ABT-869 has been studied in several completed trials. NCT00486538 evaluated it in advanced renal cell carcinoma after sunitinib treatment. NCT00517790 studied it in advanced NSCLC. NCT00716534 tested it with carboplatin and paclitaxel in advanced or metastatic NSCLC. NCT00733187 examined food effects and diurnal variation in advanced solid tumors.
ABT-869 is also known by the name linifanib. The drug has been referred to by both names in clinical research contexts. It is an investigational small molecule oncology agent developed by AbbVie.